nChroma Bio

About nChroma Bio

nChroma Bio emerged in December 2024 from the strategic merger of two Boston-area biotechnology firms, Chroma Medicine and Nvelop Therapeutics. This union created a company focused on advancing in vivo targeted genetic medicines, combining Chroma's expertise in epigenetic editing with Nvelop's non-viral, programmable delivery technologies. Concurrent with its formation, nChroma Bio secured $75 million in an oversubscribed financing round led by prominent investors including Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners, providing a multi-year operational runway.

The company operates in the biotechnology sector, specifically focusing on the development of genetic medicines to address a wide range of diseases with high unmet needs. Its business model centers on the research and development of therapeutic candidates, with a strategy that includes forming strategic partnerships with healthcare institutions and pharmaceutical companies to accelerate product development and expand market reach. The leadership team is helmed by CEO Jeff Walsh, who previously led Nvelop Therapeutics, and Jeff Marrazzo, co-founder of Spark Therapeutics, serves as the Chairman of the Board.

nChroma Bio's core technology is a modular platform that pairs therapeutic payloads with targeted delivery systems. A key differentiator is its use of epigenetic editing, a process that modulates gene expression by adding chemical tags to DNA without cutting or altering the underlying genetic sequence. This approach aims to mitigate risks associated with traditional gene-editing techniques, such as genomic rearrangements. For delivery, the company utilizes lipid nanoparticles (LNPs) for liver-specific targets and is developing engineered virus-like particles (eVLPs) for tissues outside of the liver. The lead program, CRMA-1001, is a liver-targeted epigenetic editor being developed as a potential functional cure for chronic hepatitis B and D. Preclinical studies have shown that CRMA-1001 can achieve a durable reduction of key viral biomarkers. The company plans to submit a clinical trial application for CRMA-1001 in 2025 and anticipates patient dosing to begin in 2026.